Foghorn therapeutics presents new preclinical data on novel brg1/brm inhibitor fhd-286 at the 2022 aacr annual meeting

Cambridge, mass., april 13, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data supporting the clinical development and mechanistic understanding of baf inhibition through the brg1 (smarca4) and brm (smarca2) dual inhibitor, fhd-286, for the treatment of cancer, at the 2022 american association for cancer research (aacr) annual meeting in new orleans, louisiana. fhd-286 has first-in-class potential and is foghorn's first candidate directly targeting the chromatin regulatory system to emerge from the company's gene traffic control® platform. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking